Home › Products › Oncology › Decitafect 50mg Injection
Decitafect 50mg Injection
Salt Composition: DECITABINE
- Manufacturer: AUREATE HEALTHCARE PVT LTD
- Pack Size: 1 VIAL(s)
- Dosage Form: INJECTION
- Strength: 50MG
- Prescription Required
- Storage: Do not store it above 25°C keep the injection away from the reach of children and pets. If you have missed any dosing appointments, inform your doctor and schedule immediately.
₹5067.00₹7031.25
Inclusive of all taxes
Product Introduction
Decitafect 50mg injection contains the active substance decitabine, an antineoplastic drug that belongs to the class of DNA methylation inhibitors. It is indicated for the treatment of myelodysplastic syndrome, a group of conditions characterised by bone marrow production of misshapen blood cells and insufficient generation of healthy blood cells. It is also indicated for the treatment of acute myeloid leukaemia (AML). The mechanism of action involves inhibition of cancer cell growth.
Do not use this injection if you have a known allergy to decitabine or any other ingredient in this medicine. Inform your physician if you have an active infection, decreased blood cell count, liver disease, kidney disorder, or heart disorder. This medicine is not recommended for patients below 18 years of age.
This medicine can cause a serious immune reaction known as differentiation syndrome. Report to your physician if you experience symptoms including sudden difficulty in breathing, cough, fever, or body swelling.
Decitafect 50mg injection should not be used in pregnant women or women who are breastfeeding. Inform your physician if you are pregnant or breastfeeding. Use effective contraception throughout therapy to prevent pregnancy.
Common adverse reactions include decreased white blood cell count, decreased red blood cell count, decreased platelet count, and increased body temperature.
Uses
Myelodysplastic syndromes (MDS) Acute myeloid leukemia (AML)
How it works
Decitafect 50mg injection promotes hypomethylation of DNA and cellular differentiation or cell death after phosphorylation, direct incorporation into DNA, and inhibition of DNA methyltransferase. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow.
How to Use
It will be given to you by a doctor or nurse in a hospital or clinic setting trained in cancer chemotherapy. It is given as an intravenous infusion drip (into your vein). This will take one hour. Do not self-administer the injection. Your doctor will decide the dose and duration of the treatment based on your disease severity, body weight, and other factors.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Common Swelling in the face, hands, and feet Swelling and pain in the skin Discoloration of the skin Increased blood sugar levels Decreased albumin levels Abdominal pain, constipation Decrease in appetite Diarrhea, indigestion Nausea, vomiting Insomina, dizziness Pain in limbs Serious Heart problems Anemia Infection Bleeding Fluid in the lungs Pneumonia
Expert Tips
Male patient with a female partner of reproductive potential to use effective contraception during the therapy and for 3 months after the last dose. Report symptoms of infection, anemia, or bleeding immediately to your doctor. Do not breastfeed during the treatment and for 1 week after the last dose. This medicine may cause infertility in both men and women, inform your doctor if you are planning for pregnancy before initiating the treatment. This medicine may make you bleed, bruise, or get infections more easily. Take precautions to prevent illness and injury. Wash your hands often. Your doctor may advise you to take certain tests to check for the effectiveness of the therapy.
References
- Dacogen 50 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) - (emc). www.medicines.org.uk. [Revised February 2022]. [Accessed April 21, 2023.] https://www.medicines.org.uk/emc/product/2838/smpc
- Highlights of prescribing information - decitabine; [Revised on 2013]. [Accessed April 21, 2023.] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205582s000lbl.pdf
- Issa JP. Decitabine. Current Opinion in Oncology. [revised 2003 Nov] [cited 2020 Jan 2];15(6):446â51. Available from: https://pubmed.ncbi.nlm.nih.gov/14624227/
Safety Advice
Pregnancy: unsafe Decitafect 50mg injection is unsafe to administer in pregnant women because it may affect the fetus. Inform your physician if you are pregnant, suspect pregnancy, or planning to become pregnant. Using an effective birth control method during the treatment and for 6 months after your last dose is necessary.
Lungs: Consult your doctor It is unknown whether Decitafect 50mg injection can be used in patients with lung disorders. Consult your doctor if you have any lung diseases before starting the treatment.
Breastfeeding: unsafe Breastfeeding is not recommended in patients taking Decitafect 50mg injection because the medicine passes into the breast milk in small amounts and may harm your baby.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.